3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Advanced Malignancies
1
Advanced Cancer
1
Interventions
Cisplatin
35
pembrolizumab
29
Radiotherapy
26
Cetuximab
26
Docetaxel
17
Paclitaxel
13
Fluorouracil
13
Cyclophosphamide
12
fludarabine
11
Radiotherapy, Intensity-Modulated
11
Nivolumab
10
Carboplatin
9
atezolizumab
7
Radiation
7
Gemcitabine
7
Erlotinib Hydrochloride
7
Bortezomib
7
fludarabine phosphate
6
Pemetrexed
5
Interleukin-2
5
Radiosurgery
4
Everolimus
4
Drug Therapy
4
Azacitidine
4
olaparib
3
motexafin gadolinium
3
durvalumab
3
cemiplimab
3
Trastuzumab
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Head and Neck Neoplasms
×
cabiralizumab
×
Clear all
NCT02526017
2022-03-09
FPA008-003
Five Prime Therapeutics, Inc.
Phase 1
Completed
313 enrolled
30 charts